Pinnacle Spine: New Patent for InFill

Pinnacle Spine Group, LLC is announcing the third patent covering the company’s InFill fusion technology. The patent, Intervertebral Implants and Related Tools, follows on the heels of patents related to spinal implants and methods of post-filling to provide for superior fusion results.

“This new patent significantly broadens our overall intellectual property portfolio and, from a commercial standpoint, meaningfully strengthens our patent position in the area of spinal fusion, ” said Zach Sowell, President of Pinnacle Spine, in the December 22, 2015 news release. Sowell added that “Pinnacle Spine plans to continue to work with surgeons and partners to improve the company’s systems and promote the promising technology behind the InFill family of fusion systems. We believe that maximizing contact between graft and a well-prepared endplate is the best way to promote a robust fusion. The industry clearly agrees, as we are seeing more and more devices and systems adopting in-situ graft delivery. We are proud to be trend setters and look forward to a year of growth in 2016, with many exciting projects already underway.”

Sowell told OTW, “The biggest challenge was to be sure we adequately protected the novel technology that we have brought to the industry. We are seeing rapid adoption with respect to the technology developed by Pinnacle, which tells us everything we need to know. We believe that by granting the third U.S. patent to Pinnacle, the Patent Office has recognized the unique aspects of the InFill technology. We are currently pursuing additional patent protection related to post-filling and related technologies through a number of U.S. and foreign applications.”

“As far as the next six months, we are nearing the finalization of our next generation direct lateral implant, which will continue to optimize fusion when used with our InFill Graft Delivery System. We are about to close a deal with a major player within the spinal fusion industry to expand distribution of our lateral system. We are working with various biologics companies to ensure compatibility with our systems. We are also working to develop a study to examine the increased percentage of graft-to-endplate contact when using the InFill family of fusion systems in conjunction with the InFill Graft Delivery System. We expect an exciting year in 2016!”